STAR Strides Pharma Science Q3 FY26 results (Oct–Dec 2025) and concall
Strides Pharma reported a strong Q3 FY26, driven by robust profitability and significant growth in Ex-U.S. markets, which now contribute 47% of revenues and grew 20% YoY. Gross margins exceeded 60%, and EBITDA reached a record Rs. 236 crores, up 12% YoY. The company also improved its debt/EBITDA ratio to 1.59x and ROCE to 15.8%, despite flat U.S. revenue due to seasonal factors and product discontinuations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 0.5%, net profit up 713.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 520 | 551 | 556 | 499 | 522 +0% | 554 +1% |
| EBITDA | 55 | 74 | 68 | 67 | 62 +13% | 81 +9% |
| Net profit | 17 | 15 | 16 | 13 | 32 +88% | 122 +713% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
